C4XD appoints new executive chairman
British biotech company C4X Discovery Holdings (LSE: C4XD) has appointed Dr Clive Dix as executive chairman.
Dr Dix is widely recognized as one of the leading figures in the UK biotechnology sector and brings with him a wealth of experience from both biotechnology and pharmaceutical roles.
Most recently Dr Dix was chief executive of Convergence Pharmaceuticals and has held senior positions with PowderMed, Auralis and PowderJect Pharmaceuticals. Before his move into biotechnology, he was UK research director for GlaxoSmithKline (LSE: GSK). He is currently chairman of Touchlight Genetics and Calchan and was chairman of the UK BioIndustry Association (BIA) from 2008 to 2010.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze